AstraZeneca American depository shares earlier touched their highest level in two years after the company said a phase 3 trial of Lynparza showed a “statistically-significant and clinically-meaningful improvement” in progression-free survival in patients with BRCA-mutated metastatic breast cancer compared to treatment with physician’s choice of a standard of care chemotherapy.
AZN was at $35.09 recently, having earlier traded as high as $35.27. The 52-week low is at $25.55. The trial showed that patients treated with Lynparza had a 42% reduction in risk of their disease worsening or death compared to those who received chemotherapy. The overall safety profile was consistent with previous trials.